.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Recent Advances in Treatment of Acute Myeloid Leukemia

EP. 1: Molecular Testing for AML

January 28th 2020

EP. 2: AML Induction Strategy and Molecular Testing

January 28th 2020

EP. 3: Assessment of Fitness for AML Induction Chemotherapy

January 28th 2020

EP. 4: Decision Making on Consolidation Therapy for AML

January 28th 2020

EP. 5: QUAZAR: Oral Azacitidine Maintenance in AML

January 28th 2020

EP. 6: Hypomethylating Agents for AML

January 28th 2020

EP. 7: Venetoclax-Based Regimens for Unfit Patients with AML

January 28th 2020

EP. 8: Managing Venetoclax-Associated Toxicity in AML

January 28th 2020

EP. 9: Venetoclax-Based Chemotherapy Combinations in AML

January 28th 2020

EP. 10: CPX-351 for Secondary AML

January 28th 2020

EP. 11: Previously Untreated FLT3-Mutated AML

January 28th 2020

EP. 12: Second-Generation FLT3 Inhibitors for AML

January 28th 2020

EP. 13: Relapsed/Refractory FLT3-Mutated AML

January 28th 2020

EP. 14: IDH1/2 Inhibitors in AML

January 28th 2020

EP. 15: Differentiation Syndrome and IDH1/2 Inhibitors

January 28th 2020

EP. 16: Gemtuzumab Ozogamicin for CD33+ AML and APL

January 28th 2020

EP. 17: Immune Checkpoint Inhibitors for AML

January 28th 2020

EP. 18: Novel Agents Under Investigation for AML

January 28th 2020